Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache
Public ClinicalTrials.gov record NCT00123201. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Efficacy, Safety and Tolerability Study of Dronabinol MDI in the Acute Treatment of Migraine Headache
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to evaluate the efficacy and safety of dronabinol MDI for the acute treatment of moderate to severe migraine headache.
Study identification
- NCT ID
- NCT00123201
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2005
- Primary completion
- Feb 28, 2007
- Completion
- Feb 28, 2007
- Last update posted
- Jan 15, 2015
2005 – 2007
United States locations
- U.S. sites
- 29
- U.S. states
- 17
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 10 | Huntsville | Alabama | — | — |
| Site 8 | Huntsville | Alabama | — | — |
| Site 11 | Tucson | Arizona | — | — |
| Site 3 | Anaheim | California | — | — |
| Site 6 | San Francisco | California | — | — |
| Site 15 | Stockton | California | — | — |
| Site 26 | Melbourne | Florida | — | — |
| Site 22 | New Port Richey | Florida | — | — |
| Site 18 | Orange City | Florida | — | — |
| Site 27 | Pembroke Pines | Florida | — | — |
| Site 14 | Plantation | Florida | — | — |
| Site 24 | Plantation | Florida | — | — |
| Site 7 | St. Petersburg | Florida | — | — |
| Site 25 | Atlanta | Georgia | — | — |
| Site 12 | Chicago | Illinois | — | — |
| Site 1 | Chicago | Illinois | — | — |
| Site 28 | Lexington | Kentucky | — | — |
| Site 20 | Madisonville | Kentucky | — | — |
| Site 2 | Boston | Massachusetts | — | — |
| Site 19 | Omaha | Nebraska | — | — |
| Site 29 | Clementon | New Jersey | — | — |
| Site 4 | Mount Vernon | New York | — | — |
| Site 9 | Raleigh | North Carolina | — | — |
| Site 23 | Fargo | North Dakota | — | — |
| Site 13 | Portland | Oregon | — | — |
| Site 5 | Spartanburg | South Carolina | — | — |
| Site 16 | Bryan | Texas | — | — |
| Site 17 | Colleyville | Texas | — | — |
| Site 21 | Alexandria | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00123201, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 15, 2015 · Synced Sep 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00123201 live on ClinicalTrials.gov.